Skip to content
Contactez-nous: (+33) 1 64 62 10 12
Theradiag
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English
Menu Close

Blog

  1. Home>
  2. Financial presentations>
  3. 26/10/2021: Investor Presentations

26/10/2021: Investor Presentations

  • Post author:Quentin Massé
  • Post published:26 October 2021
  • Post category:Financial presentations

Latest Press Releases

  • 18/07/2022: Theradiag reports revenue of €6.3 million for the first half of 2022, up 14.3%
    18 July 2022/
    0 Comments
  • 08/06/2022: Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
    8 June 2022/
    0 Comments
  • 31/05/2022: THERADIAG announces the launch of ez-Track1, a Point-of-Care Testing solution for therapeutic drug monitoring
    31 May 2022/
    0 Comments

Events

05 - 08 Sep 2022

TIAFT Versailles

Versailles Palais des congrès
14 - 16 Sep 2022

“27èmes Journées de la FFER”

Cité des Sciences et de l'Industrie
18 - 21 Sep 2022

IATDMCT 2022

Clarion Congress Hotel Prague
No event found!
Load More

Next financial Event

No event found!

Useful links

  • Diagnostic
  • Theranostic
  • Events
  • Register to receive our latests news

Contact Information

  • Address:14, Rue Ambroise Croizat, 77183 Croissy Beaubourg, France
  • Phone:+33 1 64 62 10 12
  • Email:info@theradiag.comOpens in your application

Follow Us

Theradiag ©
  • Home
  • Company
    • About us
    • Our history
    • A word from our CEO
    • Our management team
    • Board of directors
    • Know-how
    • Privacy policy
  • Theranostic
    • Therapeutic Drug Monitoring of Biologics – TRACKER
      • Therapeutic Drug Monitoring of Biologics
        • TDM of Biologics
        • When to perform TDM ?
        • Results interpretation
        • Therapeutic Thresholds
        • Tracker Publications
        • Guidelines
        • Frequently asked questions
      • TRACKER
        • LISA TRACKER
        • I-Tracker
        • i-Track 10
        • Immunotrol Tracker
    • Patient Stratification -PredictImmune
    • American Customers
  • Diagnostics
    • Autoimmunity
      • Reagents – Autoimmunity
      • Quality Control – Auto-Immunity
    • Other fields
    • Instrumentation
      • Theralis
      • FIDIS™
  • Services
    • Technical Documentation Download Center
  • News
    • Press Releases
    • List of upcoming events
    • Congress calendar
  • Investors
    • Welcome Message
    • Financial News
      • Register to receive our latest news
      • Press Releases
      • Financial Reports
      • Financial presentations
    • Shareholder information
      • Stock information
      • Shareholding
      • Analyst coverage
      • Letters to shareholders
      • General meeting
    • Regulated information
      • Share capital and voting rights
      • Corporate governance & internal control
      • Statutory auditors fees
      • Description of the buyback program
      • Prospectus
      • Share buyback statement
      • Charters and code of ethics / Anti-corruption
      • Other regulated information
    • Governance
      • Board of directors
      • Statute and internal regulations
      • Quiet period policy and trading windows
    • Investor contacts and registration
    • Legal notice
  • Contacts
  • Français
  • English